Dimensional Fund Advisors LP Has $72.19 Million Position in Regeneron Pharmaceuticals, Inc. (REGN)

Dimensional Fund Advisors LP increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,491 shares of the biopharmaceutical company’s stock after buying an additional 633 shares during the quarter. Dimensional Fund Advisors LP owned about 0.15% of Regeneron Pharmaceuticals worth $72,193,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Fieldpoint Private Securities LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $130,000. Sterling Investment Advisors Ltd. grew its position in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares in the last quarter. FNY Partners Fund LP grew its position in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 200 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $206,000. Finally, Dupont Capital Management Corp acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $220,000. 66.63% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, November 27th. Credit Suisse Group reaffirmed a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, September 11th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $480.00 to $380.00 in a report on Friday, December 1st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Two research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $465.40.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at $387.43 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $340.09 and a 12 month high of $543.55. The company has a market capitalization of $41,630.00, a price-to-earnings ratio of 35.19, a PEG ratio of 1.50 and a beta of 1.53. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same period in the prior year, the company earned $3.13 EPS. Regeneron Pharmaceuticals’s revenue was up 23.0% compared to the same quarter last year. sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

In other news, Director Charles A. Baker sold 2,000 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares in the company, valued at approximately $4,950,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/12/27/dimensional-fund-advisors-lp-has-72-19-million-position-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

What are top analysts saying about Regeneron Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit